These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23496317)

  • 21. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Ben-Horin S; Yavzori M; Katz L; Kopylov U; Picard O; Fudim E; Coscas D; Bar-Meir S; Goldstein I; Chowers Y
    Gut; 2011 Jan; 60(1):41-8. PubMed ID: 20519742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
    de Ridder L; Waterman M; Turner D; Bronsky J; Hauer AC; Dias JA; Strisciuglio C; Ruemmele FM; Levine A; Lionetti P;
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):503-8. PubMed ID: 26154031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between the IGF system and inflammatory markers in inflammatory bowel disease.
    Grønbaek H; Eivindson MV
    Aliment Pharmacol Ther; 2006 Feb; 23(4):553-4; author reply 554-5. PubMed ID: 16441476
    [No Abstract]   [Full Text] [Related]  

  • 26. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY; Sanderson JD; Irving PM
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice.
    Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V
    Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease.
    Krane MK; Allaix ME; Zoccali M; Umanskiy K; Rubin MA; Villa A; Hurst RD; Fichera A
    Dis Colon Rectum; 2013 Apr; 56(4):449-57. PubMed ID: 23478612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis.
    Pola S; Fahmy M; Evans E; Tipps A; Sandborn WJ
    Am J Gastroenterol; 2013 May; 108(5):857-8. PubMed ID: 23644970
    [No Abstract]   [Full Text] [Related]  

  • 32. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Biological drugs in inflammatory bowel disease: Management and care].
    Guerra I; Bermejo F
    Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
    [No Abstract]   [Full Text] [Related]  

  • 35. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commentary on "pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD".
    Leung E
    South Med J; 2015 Mar; 108(3):144. PubMed ID: 25772046
    [No Abstract]   [Full Text] [Related]  

  • 37. The usefulness of PPD testing in inflammatory bowel disease patients before infliximab therapy.
    Uthman I; Sharara A
    Clin Gastroenterol Hepatol; 2004 Sep; 2(9):xxii. PubMed ID: 15354286
    [No Abstract]   [Full Text] [Related]  

  • 38. [Anti-TNF agents in inflammatory bowel disease: indications and management].
    Cocq P; Yazdanpannah Y; Mesnard B; Colombel JF
    Gastroenterol Clin Biol; 2004 May; 28(5 Suppl):D61-9. PubMed ID: 15213665
    [No Abstract]   [Full Text] [Related]  

  • 39. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.